NCT04806893View on ClinicalTrials.gov

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

November 15, 2023

Study Completion Date

February 28, 2024

Conditions
Cardiovascular Risk FactorCardiovascular DiseasesCardiovascular StrokeHypercholesterolemia
Interventions
DRUG

lerodalcibep

300 mg subcutaneous injection every month (Q4W)

OTHER

Placebo

matching subcutaneous injection every month (Q4W)

Trial Locations (6)

12000

Department of Medicine, Hadassah University Hospital, Jerusalem

45219

Sterling Research Group, Cincinnati

The Lindner Research Center, Cincinnati

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

49100

Rabin Medical Center, Beilinson Hospital,, Petah Tikva

110002

G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY

NCT04806893 - Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction | Biotech Hunter | Biotech Hunter